{
    "clinical_study": {
        "@rank": "163170", 
        "arm_group": [
            {
                "arm_group_label": "ASP1517 low dose group", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "ASP1517 middle dose group", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "ASP1517 high dose group", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo group", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is to evaluate the safety and the dose-response of ASP1517  in the treatment of\n      anemia in non-dialysis Chronic Kidney Disease (CKD) patients when ASP1517 is applied\n      intermittently."
        }, 
        "brief_title": "ASP1517 Phase 2 Clinical Trial - Double-Blind Study of ASP1517 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis-", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Anemia in Chronic Kidney Disease Patients Not on Dialysis", 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Kidney Diseases", 
                "Renal Insufficiency, Chronic", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "To evaluate the safety and the dose-response of ASP1517 on Hemoglobin (Hb) correction in the\n      treatment of anemia in non-dialysis Chronic Kidney Disease (CKD) patients when ASP1517 is\n      applied intermittently.  Patients will receive ASP1517 three times a week (TIW) for first\n      6weeks.  Patients may have the second-randomization to TIW dosing or once-a-week (QW) dosing\n      at Week 6, 8, 10, 12, 14 or 16 if patients meet the criteria."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Chronic kidney disease with an estimated glomerular filtration rate (as calculated by\n             the Japanese GFR estimation equation) of >=15 and =<89 mL/min/1.73 m2, and not\n             required dialysis for 3 months since study completion\n\n          -  The mean of two Hb values at screening test and Hb test (at least one week apart form\n             the screening test) is <10.0 g/dL, with a difference of \u22641.0 g/dL between the two\n             values\n\n          -  Both TSAT>=5% and ferritin >=30 ng/mL at screening test\n\n          -  Serum folate \u22654.0 ng/mL and Vitamin B12 \u2265180 pg/mL at screening test\n\n        Exclusion Criteria:\n\n          -  Proliferative retinopathy, age-related macular degeneration, retinal vein occlusion\n             and/or macular edema that is considered to require treatment\n\n          -  Immunological disease with severe inflammation as assessed by the Investigator; even\n             if the inflammation is in remission, the subject is excluded (e.g. lupus\n             erythematosus, rheumatoid arthritis, Sjogren's syndrome, celiac disease, etc).\n\n          -  Having a history of gastric/intestinal resection considered influential on the\n             absorption of the drug in the gastrointestinal tract or evidence of active\n             gastroparesis.\n\n          -  Uncontrollable hypertension (more than one third blood pressure values of diastolic\n             BP >100 mmHg within 16 weeks prior to screening test including)\n\n          -  Congestive heart failure (NYHA classification III or higher)\n\n          -  Having a history of hospitalization for stroke, myocardial infarction or lung\n             infarction within 24 weeks before screening test\n\n          -  Positive for any of the following: anti-hepatitis C virus antibody (anti-HCV Ab);\n             hepatitis B surface antigen (HBsAg); or human immunodeficiency virus (HIV)\n\n          -  Anemia other than anemia due to low/absent renal production of EPO (e.g., iron\n             deficiency anemia, hemolytic anemia, pancytopenia, etc)\n\n          -  Using ESA, anabolic androgenic steroid, testosterone enanthate or mepitiostane within\n             6 weeks before screening test"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "74 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01964196", 
            "org_study_id": "1517-CL-0303"
        }, 
        "intervention": {
            "arm_group_label": [
                "ASP1517 low dose group", 
                "ASP1517 middle dose group", 
                "ASP1517 high dose group"
            ], 
            "description": "Oral administration", 
            "intervention_name": "ASP1517", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Renal anemia", 
            "Chronic Renal Failure", 
            "ASP1517"
        ], 
        "lastchanged_date": "October 15, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chubu", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hokkaido", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansai", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kanto", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyushu", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shikoku", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "4", 
        "official_title": "ASP1517 Phase 2 Clinical Trial -A Multi-center, Randomized, Parallel Groups, Placebo-controlled, Double-Blind Study of ASP1517 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis-", 
        "overall_contact": {
            "email": "clintrialtrials_info@jp.astellas.com", 
            "last_name": "Clinical Development Administration Dept"
        }, 
        "overall_official": {
            "affiliation": "Astellas Pharma Inc", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Rate of rise in Hb (g/dL/week) at Week 6", 
            "safety_issue": "No", 
            "time_frame": "Baseline and at 6 weeks after dosing"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01964196"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "responder is defined as a Hb \u226510.0 g/dL and an increase in Hb by \u22651.0 g/dL", 
                "measure": "Percentage of cumulative number of responder patients", 
                "safety_issue": "No", 
                "time_frame": "for 28 weeks after dosing"
            }, 
            {
                "measure": "Percentage of visits at which patients maintain Hb between 10.0-12.0 g/dL after achieving Hb \u226510.0 g/dL for each patients", 
                "safety_issue": "No", 
                "time_frame": "for 28 weeks after dosing"
            }, 
            {
                "measure": "Percentage of patients who maintain Hb between 10.0-12.0 g/dL at each visit", 
                "safety_issue": "No", 
                "time_frame": "Before and Week-2, -3, -4, -6, -8, -10, -12, -14, -16, -18, -20, -22, -24 and -28"
            }, 
            {
                "measure": "Change from baseline in Hb", 
                "safety_issue": "No", 
                "time_frame": "Before and Week-2, -3, -4, -6, -8, -10, -12, -14, -16, -18, -20, -22, -24 and -28"
            }, 
            {
                "measure": "Safety assessed as the incidence of adverse events, vital signs, 12-lead ECGs and lab-tests", 
                "safety_issue": "No", 
                "time_frame": "for 28 weeks after dosing"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}